{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:32:13Z","timestamp":1789824733185,"version":"4.0.1"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Vitamin D deficiency is an important contributor to the development of hyperparathyroidism and is independently associated with cardiovascular and bone disease. The hypothesis was that nutritional vitamin D (ergocalciferol) supplementation in children with CKD stages 2\u20134 delays the onset of secondary hyperparathyroidism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>A randomized, double-blinded, placebo-controlled study in children with CKD2\u20134 who had 25-hydroxyvitamin D [25(OH)D] deficiency was conducted. Ergocalciferol (or a matched placebo) was given daily as per Kidney Disease Outcomes Quality Initiative guidelines. The primary endpoint was the time to development of hyperparathyroidism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy-two children were screened. Forty-seven children were 25(OH)D-deficient and randomly assigned to receive ergocalciferol or placebo. Twenty children in each arm completed the study; median follow-up was 12 months. Groups were well matched for age, race, estimated GFR, and season when recruited. Nine of 20 children on placebo and 3 of 20 children on ergocalciferol developed hyperparathyroidism (odds ratio, 4.64; 95% confidence interval, 1.02\u201321.00). The time to development of hyperparathyroidism was significantly longer with ergocalciferol treatment compared with placebo (hazard ratio, 0.30; 95% confidence interval, 0.09\u20130.93,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.05). With ergocalciferol treatment, normal 25(OH)D levels were achieved in all 8 children with CKD2, 8 of 11 children with CKD3, but not in the single patient with CKD4. There were no ergocalciferol-related adverse events. 25(OH)D levels &gt;100 nmol\/L were required to achieve normal levels of 1,25-dihydroxyvitamin D.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ergocalciferol is an effective treatment that delays the development of secondary hyperparathyroidism in children with CKD2\u20133.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.04760511","type":"journal-article","created":{"date-parts":[[2012,1,20]],"date-time":"2012-01-20T20:50:19Z","timestamp":1327092619000},"page":"216-223","source":"Crossref","is-referenced-by-count":99,"title":["Ergocalciferol Supplementation in Children with CKD Delays the Onset of Secondary Hyperparathyroidism"],"prefix":"10.2215","volume":"7","author":[{"given":"Rukshana","family":"Shroff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambrose","family":"Gullett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Shute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Knott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Aitkenhead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahee","family":"Manickavasagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"van\u2019t Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-5-20230811","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease.","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"key":"R3-5-20230811","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00467-007-0684-y","article-title":"What parathyroid hormone levels should we aim for in children with stage 5 chronic kidney disease; what is the evidence?","volume":"23","author":"Rees","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"R4-5-20230811","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00467-010-1691-y","article-title":"Uraemic vasculopathy in children with chronic kidney disease: Prevention or damage limitation?","volume":"26","author":"Shroff","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"R5-5-20230811","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/01.CIR.0000020222.63035.C0","article-title":"Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure.","volume":"106","author":"Oh","year":"2002","journal-title":"Circulation"},{"key":"R6-5-20230811","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1681\/ASN.2006121397","article-title":"Mineral metabolism and vascular damage in children on dialysis.","volume":"18","author":"Shroff","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R7-5-20230811","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1093\/ndt\/gfq606","article-title":"Vitamin D status and clinical outcomes in incident dialysis patients: Results from the NECOSAD study.","volume":"26","author":"Drechsler","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R8-5-20230811","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/ki.2010.189","article-title":"Kidney bone disease and mortality in CKD: Revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.","volume":"117","author":"Kalantar-Zadeh","year":"2010","journal-title":"Kidney Int Suppl"},{"key":"R9-5-20230811","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/eurjhf\/hfr016","article-title":"Parathyroid hormone and vitamin D\u2014markers for cardiovascular and all cause mortality in heart failure.","volume":"13","author":"Schierbeck","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"R10-5-20230811","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00467-005-2082-7","article-title":"Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines.","volume":"21","author":"Klaus","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"R11-5-20230811","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency.","volume":"357","author":"Holick","year":"2007","journal-title":"N Engl J Med"},{"key":"R12-5-20230811","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s00467-010-1499-9","article-title":"The virtues of vitamin D\u2014but how much is too much?","volume":"25","author":"Shroff","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"R13-5-20230811","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1053\/j.ajkd.2005.02.029","article-title":"Prevalence of calcidiol deficiency in CKD: A cross-sectional study across latitudes in the United States.","volume":"45","author":"LaClair","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R14-5-20230811","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1136\/adc.2007.134866","article-title":"Vitamin D deficiency in children with renal disease.","volume":"93","author":"Belostotsky","year":"2008","journal-title":"Arch Dis Child"},{"key":"R15-5-20230811","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1007\/s00467-010-1639-2","article-title":"Vitamin D insufficiency and effect of cholecalciferol in children with chronic kidney disease.","volume":"25","author":"Hari","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"R16-5-20230811","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00467-008-0842-x","article-title":"Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease.","volume":"23","author":"Menon","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"R17-5-20230811","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jpeds.2008.12.006","article-title":"Vitamin D insufficiency and deficiency in children with early chronic kidney disease.","volume":"154","author":"Seeherunvong","year":"2009","journal-title":"J Pediatr"},{"key":"R18-5-20230811","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1542\/peds.2008-0634","article-title":"Vitamin D deficiency in children with chronic kidney disease: Uncovering an epidemic.","volume":"123","author":"Ali","year":"2009","journal-title":"Pediatrics"},{"key":"R19-5-20230811","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.ki.5000045","article-title":"Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation.","volume":"69","author":"Andress","year":"2006","journal-title":"Kidney Int"},{"key":"R20-5-20230811","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"key":"R21-5-20230811","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.","volume":"349","author":"Teng","year":"2003","journal-title":"N Engl J Med"},{"key":"R22-5-20230811","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/sj.ki.5001868","article-title":"Mortality risk among hemodialysis patients receiving different vitamin D analogs.","volume":"70","author":"Tentori","year":"2006","journal-title":"Kidney Int"},{"key":"R23-5-20230811","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/sj.ki.5000394","article-title":"25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells.","volume":"70","author":"Ritter","year":"2006","journal-title":"Kidney Int"},{"key":"R26-5-20230811","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.ajkd.2007.04.010","article-title":"Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD.","volume":"50","author":"Al-Aly","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"R27-5-20230811","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4158\/EP.14.1.10","article-title":"Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: A randomized controlled pilot study.","volume":"14","author":"Chandra","year":"2008","journal-title":"Endocr Pract"},{"key":"R28-5-20230811","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1440-1797.2006.00698.x","article-title":"Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25-hydroxyvitamin D in chronic kidney disease.","volume":"11","author":"DeVille","year":"2006","journal-title":"Nephrology (Carlton"},{"key":"R29-5-20230811","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/08860220801964210","article-title":"Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients.","volume":"30","author":"Dogan","year":"2008","journal-title":"Ren Fail"},{"key":"R30-5-20230811","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000157177","article-title":"Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease.","volume":"31","author":"Oksa","year":"2008","journal-title":"Kidney Blood Press Res"},{"key":"R31-5-20230811","first-page":"75","article-title":"Vitamin D insufficiency and treatment with oral vitamin D3 in northern-dwelling patients with chronic kidney disease.","volume":"22","author":"Rucker","year":"2009","journal-title":"J Nephrol"},{"key":"R32-5-20230811","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000098561","article-title":"Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.","volume":"27","author":"Zisman","year":"2007","journal-title":"Am J Nephrol"},{"key":"R33-5-20230811","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00467-007-0459-5","article-title":"Progression of chronic renal failure in children with dysplastic kidneys.","volume":"22","author":"Gonz\u00e1lez Celed\u00f3n","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"R34-5-20230811","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1373\/clinchem.2005.052936","article-title":"Routine isotope-dilution liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of the 25-hydroxy metabolites of vitamins D2 and D3.","volume":"51","author":"Maunsell","year":"2005","journal-title":"Clin Chem"},{"key":"R35-5-20230811","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1681\/ASN.2007090993","article-title":"A bimodal association of vitamin D levels and vascular disease in children on dialysis.","volume":"19","author":"Shroff","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R36-5-20230811","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/ajcn\/78.3.496a","article-title":"Serum 25-hydroxyvitamin D response to oral vitamin D intake in children.","volume":"78","author":"Zittermann","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"R37-5-20230811","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jbmr.328","article-title":"Why the IOM recommendations for vitamin D are deficient.","volume":"26","author":"Heaney","year":"2011","journal-title":"J Bone Miner Res"},{"key":"R38-5-20230811","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1210\/jc.2004-0360","article-title":"Vitamin D2 is much less effective than vitamin D3 in humans.","volume":"89","author":"Armas","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R39-5-20230811","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1210\/jc.2007-2308","article-title":"Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D.","volume":"93","author":"Holick","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R40-5-20230811","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00467-008-1041-5","article-title":"A single high dose of ergocalciferol can be used to boost 25-hydroxyvitamin D levels in children with kidney disease.","volume":"24","author":"Belostotsky","year":"2009","journal-title":"Pediatr Nephrol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201202000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:41:52Z","timestamp":1786369312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201202000-00005"}},"subtitle":["A Randomized Trial"],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.04760511","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}